var data={"title":"Alpha-1 proteinase inhibitor: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alpha-1 proteinase inhibitor: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5591?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alpha-1-proteinase-inhibitor-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alpha-1 proteinase inhibitor: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131976\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aralast NP;</li>\n      <li>Glassia;</li>\n      <li>Prolastin-C;</li>\n      <li>Zemaira</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131977\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Prolastin-C</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131989\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antitrypsin Deficiency Agent;</li>\n      <li>\n        Blood Product Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131978\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>The vial strength (mg) of some products (ie, Prolastin-C, Zemaira) varies by manufacturer lot; consult individual vial labels for exact amount prior to preparation for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alpha<sub>1</sub>-antitrypsin deficiency:</b> IV: 60 mg/kg once weekly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131979\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671398\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671399\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131961\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glassia: 1000 mg/50 mL (1 ea) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prolastin-C: 1000 mg/20 mL (1 ea) [latex free, pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aralast NP: 400 mg (1 ea [DSC]); 500 mg (1 ea); 800 mg (1 ea [DSC]); 1000 mg (1 ea) [contains polyethylene glycol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prolastin-C: 1000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemaira: 1000 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131949\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50620846\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50640777\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Prolastin-C liquid: FDA approved September 2017; availability anticipated in 2018. Information pertaining to this product within the monograph is pending revision. Prolastin-C liquid is supplied in a 1,000 mg (approximate) single-use vial containing 20 mL of solution for injection. The actual amount of functionally active Alpha1-PI in milligrams is printed on the vial label and carton. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131963\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For IV infusion only. Do not mix with other agents or solutions. If adverse reactions occur during administration, rate may be decreased or temporarily interrupted. Some products require an in-line filter for administration; consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aralast NP, Glassia: Infuse at rate of &le;0.2 mL/kg/minute. Glassia may be self-administered by the patient/caregiver at home after appropriate training</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prolastin-C, Zemaira: Infuse at ~0.08 mL/kg/minute (rate may be increased or decreased based on patient comfort).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prolastin-C Liquid: Infuse at 0.08 mL/kg/minute (takes ~15 minutes to infuse) as determined by patient response and comfort. Allow vial to warm to room temperature before administration; solution may contain a few protein particles.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131962\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alpha<sub>1</sub>-proteinase inhibitor deficiency:</b> Long-term augmentation and maintenance therapy in adults with severe hereditary deficiency of alpha<sub>1</sub>-antitrypsin (AAT) with clinically evident emphysema.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Not indicated as therapy for patients with lung disease in whom hereditary AAT deficiency has not been established; long-term effects of chronic augmentation or maintenance therapy of individuals with alpha<sub>1</sub>-proteinase inhibitor are not available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The effect of augmentation therapy with any alpha<sub>1</sub>-proteinase inhibitor on pulmonary exacerbations has not been demonstrated in randomized, controlled clinical trials. However, one randomized controlled trial showed a reduction in emphysema progression with alpha<sub>1</sub>-proteinase inhibitor augmentation therapy when CT lung density was measured at total lung capacity (Chapman 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131956\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Actual incidence may vary by product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bruising at injection site (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (discomfort: &le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory tract infection (&le;96%), exacerbation of chronic obstructive pulmonary disease (&le;38%), cough (&le;24%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (&le;8%), chest discomfort (&le;6%), vasodilatation (&ge;5%), peripheral edema (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;6%), fatigue (&le;6%), chills (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&le;4%), urticaria (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (&le;6%), sore throat (&ge;5%), oral candidiasis (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&ge;5%), back pain (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinorrhea (&le;6%), sinusitis (&le;6%), bronchitis (&ge;5%), rhinitis (&ge;5%), dyspnea (&le;5%), pharyngitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abdominal distention, abdominal pain, anaphylactoid reaction, anaphylaxis, arthralgia, asthma, confusion, conjunctivitis, drowsiness, dysmenorrhea, exfoliative dermatitis, facial edema, feeling abnormal, flu-like symptoms, flushing, hyperhidrosis, hypersensitivity reaction, hypertonia, hypoesthesia, hypotension, hypoxia, increased blood pressure, injection site reaction, insomnia, lip edema, lymph node pain, malaise, nervousness, pain, paresthesia, periorbital swelling, pharyngeal edema, pulmonary disease, skin rash, syncope, tachycardia, tinnitus, visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131966\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of anaphylaxis or other severe systemic reaction to A<sub>1</sub>-proteinase inhibitor or any component of the formulation; IgA deficient patients with antibodies against IgA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131953\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe hypersensitivity and anaphylactic/anaphylactoid reactions may occur; stop infusion promptly for acute hypersensitivity; immediate treatment (including epinephrine and/or other supportive therapy) should be available. Monitor vital signs and observe the patient throughout the infusion. May contain trace amounts of IgA; patients with known anti-IgA antibody, which may be present in patients with selective or severe IgA deficiency, have an increased risk of developing potentially severe hypersensitivity and anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Plasma volume may increase following infusion; use with caution in patients at risk for fluid overload.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease (eg, viruses and theoretically the Creutzfeldt-Jakob disease [CJD]). Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298714\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6217702\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8495&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131958\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131967\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21098360\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if alpha<sub>1</sub>-proteinase inhibitor is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131968\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131959\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Alpha<sub>1</sub>-PI serum levels; lung function; vital signs during infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131952\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alpha<sub>1</sub>-antitrypsin (AAT) is the principle protease inhibitor in  serum. Its major physiologic role is to render proteolytic enzymes (secreted during inflammation) inactive. A decrease in AAT, as seen in congenital AAT deficiency, leads to increased elastic damage in the lung, causing emphysema.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131965\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~3.5 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Metabolic: ~5-6 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~1 hour; threshold levels achieved after 3 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322971\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Glassia Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/50 mL (0 Price provided is per milligram): $0.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Prolastin-C Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/20 mL (1): $0.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Aralast NP Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (0 Price provided is per milligram): $0.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (0 Price provided is per milligram): $0.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Prolastin-C Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (0 Price provided is per milligram): $0.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zemaira Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (0 Price provided is per milligram): $0.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131969\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alfalastin (FR);</li>\n      <li>Aralast (GR);</li>\n      <li>Glassia (IL);</li>\n      <li>Prolastin (AT, CH, DE, GR, IE, NL, PL, PT);</li>\n      <li>Prolastin-C (AR, AU, BB);</li>\n      <li>Prolastina (DK, ES, FI, IT, NO, SE);</li>\n      <li>Pulmolast (BE);</li>\n      <li>Respikam (RU);</li>\n      <li>Respreeza (CZ, ES, GB, IE);</li>\n      <li>Trypsone (CZ);</li>\n      <li>Zemaira (AU, NZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society/European Respiratory Society Statement: &ldquo;Standards for the Diagnosis and Management of Individuals With Alpha-1 Antitrypsin Deficiency,&rdquo; <i>Am J Respir Crit Care Med</i>, 2003, 168(7):818-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/14522813/pubmed\" target=\"_blank\" id=\"14522813\">14522813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aralast NP (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Westlake Village, CA: Baxalta US Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe &alpha;1 antitrypsin deficiency(RAPID): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2015;386(9991):360-368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/26026936/pubmed\" target=\"_blank\" id=\"26026936\">26026936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glassia (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Lexington, MA: Baxalta US Inc: June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie SG, Sclar DA, and Gill MA, &ldquo;Aralast: A New Alpha1-Protease Inhibitor for Treatment of Alpha-Antitrypsin Deficiency,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(11):1861-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/16219903/pubmed\" target=\"_blank\" id=\"16219903\">16219903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prolastin-C (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics, Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prolastin-C Liquid (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics, Inc; September 2017</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stoller JK and Aboussouan LS, &ldquo;Alpha1-Antitrypsin Deficiency,&rdquo; <i>Lancet</i>, 2005, 365(9478):2225-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alpha-1-proteinase-inhibitor-drug-information/abstract-text/15978931/pubmed\" target=\"_blank\" id=\"15978931\">15978931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zemaira (alpha<sub>1</sub>-proteinase inhibitor, human) [prescribing information]. Kankakee, IL: CSL Behring; May 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8495 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F131976\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F131977\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F131989\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F131978\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F131979\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671398\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671399\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F131961\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F131949\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50620846\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50640777\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F131963\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F131962\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131956\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F131966\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F131953\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298714\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6217702\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F131958\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F131967\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21098360\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F131968\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F131959\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F131952\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F131965\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322971\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F131969\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8495|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alpha-1-proteinase-inhibitor-patient-drug-information\" class=\"drug drug_patient\">Alpha-1 proteinase inhibitor: Patient drug information</a></li></ul></div></div>","javascript":null}